Stock Research: Calliditas Therapeutics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Calliditas Therapeutics

OM:CALTX SE0010441584
n/a
  • Value
    n/a
  • Growth
    n/a
  • Safety
    Safety
    n/a
  • Combined
    n/a
  • Sentiment
    n/a
  • 360° View
    360° View
    n/a
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description
Analysis
n/a
more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: .

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
n/a n/a 19 18
Growth
n/a n/a 71 77
Safety
Safety
n/a n/a 10 51
Sentiment
n/a n/a 58 58
360° View
360° View
n/a n/a 20 44
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
n/a n/a 100 87
Opinions Change
n/a n/a 50 50
Pro Holdings
n/a n/a 49 54
Market Pulse
n/a n/a 21 23
Sentiment
n/a n/a 58 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
n/a n/a 19 18
Growth
n/a n/a 71 77
Safety Safety
n/a n/a 10 51
Combined
n/a n/a 8 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
n/a n/a 83 94
Price vs. Earnings (P/E)
n/a n/a 48 19
Price vs. Book (P/B)
n/a n/a 3 38
Dividend Yield
n/a n/a 1 1
Value
n/a n/a 19 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
n/a n/a 98 100
Profit Growth
n/a n/a 14 21
Capital Growth
n/a n/a 47 96
Stock Returns
n/a n/a 74 28
Growth
n/a n/a 71 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
n/a n/a 14 93
Refinancing
n/a n/a 31 50
Liquidity
n/a n/a 17 1
Safety Safety
n/a n/a 10 51

Similar Stocks

Discover high‑ranked alternatives to Calliditas Therapeutics and broaden your portfolio horizons.

thyssenkrupp

XTRA:TKA
Country: Germany
Industry: Steel
Size: X-Large
Full Stock Analysis

SKF

OM:SKF B
Country: Sweden
Industry: Industrial Machinery
Size: Large
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.